Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)
Aufreinigung
MADD Antibody is Antibody is DEAE purified.
Immunogen
MADD antibody was raised against a peptide corresponding to amino acids near the carboxy terminus of human MADD. The immunogen is located within the last 50 amino acids of MADD.
MADD
Reaktivität: Maus
IF (p), IF (cc)
Wirt: Kaninchen
Polyclonal
AbBy Fluor® 488
Applikationshinweise
MADD antibody can be used for detection of MADD by Western blot at 1 - 2 mg/mL. 200 to 220 kDa bands should be detected. Antibody can also be used for immunocytochemistry starting at 10 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human and mouse samples, Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
MADD Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
MADD antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
MADD antikoerper, MGC145371 antikoerper, DENN antikoerper, IG20 antikoerper, RAB3GEP antikoerper, 9630059K23Rik antikoerper, MAP kinase activating death domain antikoerper, MAP-kinase activating death domain antikoerper, MADD antikoerper, madd antikoerper, Madd antikoerper
Hintergrund
MADD Antibody: MAP kinase-activating death domain protein (MADD) was initially identified as the type 1 tumor necrosis factor receptor (TNFR1) associated protein though their death domains. Overexpression of MADD activates MAP kinases ERK and JNK and induces the phosphorylation of cytosolic phospholipase A2. MADD shares 98 % identity with DENN (for differentially expressed in neoplastic vs. normal cells), which was recently identified as a substrate for c-jun N-terminal kinase 3 (JNK3). MADD has greater than 94 % overall identity to a GDP/GTP exchange protein Rab3-GEP. MADD is 87 % identical to KIAA0358, a brain protein of unknown function. Identification of MADD as a component of the TNFR1 signaling complex and the similarity between MADD and Rab3-GEP provides a connection between TNFR1 activation and downstream MAP kinase activity through a guanine-nucleotide exchange protein.